OBJECTIVE: The new criteria for preclinical Alzheimer disease (AD) proposed 3 stages: abnormal levels of β-amyloid (stage 1), stage 1 plus evidence of brain injury (stage 2), and stage 2 plus subtle cognitive changes (stage 3). However, a large group of subjects with normal β-amyloid biomarkers have evidence of brain injury; we labeled them as the "suspected non-Alzheimer pathophysiology" (sNAP) group. The characteristics of the sNAP group are poorly understood. METHODS: Using the preclinical AD classification, 430 cognitively normal subjects from the Mayo Clinic Study of Aging who underwent brain magnetic resonance (MR), (18)fluorodeoxyglucose (FDG), and Pittsburgh compound B positron emission tomography (PET) were evaluated for FDG PET regional volumetrics, MR regional brain volumetrics, white matter hyperintensity volume, and number of infarcts. We examined cross-sectional associations across AD preclinical stages, those with all biomarkers normal, and the sNAP group. RESULTS: The sNAP group had a lower proportion (14%) with apolipoprotein E ε4 genotype than the preclinical AD stages 2 + 3. The sNAP group did not show any group differences compared to stages 2 + 3 of the preclinical AD group on measures of FDG PET regional hypometabolism, MR regional brain volume loss, cerebrovascular imaging lesions, vascular risk factors, imaging changes associated with α-synucleinopathy, or physical findings of parkinsonism. INTERPRETATION: Cognitively normal persons with brain injury biomarker abnormalities, with or without abnormal levels of β-amyloid, were indistinguishable on a variety of imaging markers, clinical features, and risk factors. The initial appearance of brain injury biomarkers that occurs in cognitively normal persons with preclinical AD may not depend on β-amyloidosis.
OBJECTIVE: The new criteria for preclinical Alzheimer disease (AD) proposed 3 stages: abnormal levels of β-amyloid (stage 1), stage 1 plus evidence of brain injury (stage 2), and stage 2 plus subtle cognitive changes (stage 3). However, a large group of subjects with normal β-amyloid biomarkers have evidence of brain injury; we labeled them as the "suspected non-Alzheimer pathophysiology" (sNAP) group. The characteristics of the sNAP group are poorly understood. METHODS: Using the preclinical AD classification, 430 cognitively normal subjects from the Mayo Clinic Study of Aging who underwent brain magnetic resonance (MR), (18)fluorodeoxyglucose (FDG), and Pittsburgh compound B positron emission tomography (PET) were evaluated for FDG PET regional volumetrics, MR regional brain volumetrics, white matter hyperintensity volume, and number of infarcts. We examined cross-sectional associations across AD preclinical stages, those with all biomarkers normal, and the sNAP group. RESULTS: The sNAP group had a lower proportion (14%) with apolipoprotein E ε4 genotype than the preclinical AD stages 2 + 3. The sNAP group did not show any group differences compared to stages 2 + 3 of the preclinical AD group on measures of FDG PET regional hypometabolism, MR regional brain volume loss, cerebrovascular imaging lesions, vascular risk factors, imaging changes associated with α-synucleinopathy, or physical findings of parkinsonism. INTERPRETATION: Cognitively normal persons with brain injury biomarker abnormalities, with or without abnormal levels of β-amyloid, were indistinguishable on a variety of imaging markers, clinical features, and risk factors. The initial appearance of brain injury biomarkers that occurs in cognitively normal persons with preclinical AD may not depend on β-amyloidosis.
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: C R Jack; M M Shiung; S D Weigand; P C O'Brien; J L Gunter; B F Boeve; D S Knopman; G E Smith; R J Ivnik; E G Tangalos; R C Petersen Journal: Neurology Date: 2005-10-25 Impact factor: 9.910
Authors: Rahul S Desikan; Linda K McEvoy; Wesley K Thompson; Dominic Holland; James B Brewer; Paul S Aisen; Reisa A Sperling; Anders M Dale Journal: Arch Neurol Date: 2012-06
Authors: Julie C Price; William E Klunk; Brian J Lopresti; Xueling Lu; Jessica A Hoge; Scott K Ziolko; Daniel P Holt; Carolyn C Meltzer; Steven T DeKosky; Chester A Mathis Journal: J Cereb Blood Flow Metab Date: 2005-11 Impact factor: 6.200
Authors: D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen Journal: J Neuropathol Exp Neurol Date: 2003-11 Impact factor: 3.685
Authors: Laura E M Wisse; Nirali Butala; Sandhitsu R Das; Christos Davatzikos; Bradford C Dickerson; Sanjeev N Vaishnavi; Paul A Yushkevich; David A Wolk Journal: Neurobiol Aging Date: 2015-09-07 Impact factor: 4.673
Authors: Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos Journal: Nat Rev Neurol Date: 2016-01-18 Impact factor: 42.937
Authors: Patrick Reilly; Charisse N Winston; Kelsey R Baron; Margarita Trejo; Edward M Rockenstein; Johnny C Akers; Najla Kfoury; Marc Diamond; Eliezer Masliah; Robert A Rissman; Shauna H Yuan Journal: Neurobiol Dis Date: 2017-06-10 Impact factor: 5.996
Authors: David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Erin L Abner; Richard J Kryscio; Frederick A Schmitt; David W Fardo; Daniela C Moga; Eseosa T Ighodaro; Gregory A Jicha; Lei Yu; Hiroko H Dodge; Chengjie Xiong; Randall L Woltjer; Julie A Schneider; Nigel J Cairns; David A Bennett; Peter T Nelson Journal: Ann Neurol Date: 2017-03-22 Impact factor: 10.422
Authors: Rosebud O Roberts; David S Knopman; Ruth H Cha; Michelle M Mielke; V Shane Pankratz; Bradley F Boeve; Kejal Kantarci; Yonas E Geda; Clifford R Jack; Ronald C Petersen; Val J Lowe Journal: J Nucl Med Date: 2014-03-20 Impact factor: 10.057